IGM Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 224
- Market Cap
- $606.8M
- Website
- http://www.igmbio.com
- Introduction
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Clinical Trials
12
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
- Conditions
- Idiopathic Inflammatory MyopathiesInflammatory Myopathies
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT06524687
- Locations
- 🇺🇸
Standford University, Palo Alto, California, United States
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
- Conditions
- Relapsed/Refractory Non-Hodgkin Lymphomas
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- IGM Biosciences, Inc.
- Registration Number
- NCT06331832
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇰🇷Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
🇪🇸START-Madrid Centro Integral Oncologico Clara Campal, Madrid, Spain
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
- Conditions
- Rheumatoid ArthritisArthritis, RheumatoidArthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT06087406
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States
🇺🇸Triwest Research Associates, San Diego, California, United States
🇺🇸East Bay Rheumatology Medical Group, San Leandro, California, United States
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus ErythematosusLupus Erythematosus
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT06041568
- Locations
- 🇺🇸
TriWest Research Associates, San Diego, California, United States
🇺🇸East Bay Rheumatology, San Leandro, California, United States
🇺🇸Omega Research, DeBary, DeBary, Florida, United States
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- IGM Biosciences, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05908396
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Prev
- 1
- 2
- Next
News
Concentra Biosciences Acquires Cargo Therapeutics for $202M Following CAR-T Trial Failure
Cargo Therapeutics agreed to be acquired by Concentra Biosciences for approximately $202 million upfront after halting development of its lead CAR-T therapy firicabtagene autoleucel due to poor durability results.
IGM Biosciences Halts Autoimmune Programs, Imvotamab and IGM-2644, Following Disappointing Phase 1b Results
IGM Biosciences has stopped the development of imvotamab and IGM-2644 after Phase 1b trials showed insufficient B cell depletion in rheumatoid arthritis and lupus patients.
Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments
Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.
Biopharma Job Market Shows Signs of Recovery Despite Continued Layoffs in 2024
Biopharma job postings declined 16% year-over-year in Q4 2024, with at least 24,000 industry professionals laid off throughout the year, including major cuts at Johnson & Johnson, Bristol Myers Squibb, and Bayer.
Candid Therapeutics Launches with $370M to Advance Bispecific T-Cell Engagers for Autoimmune Diseases
• Candid Therapeutics launched with $370 million in funding to develop bispecific T-cell engagers for autoimmune diseases, acquiring two private biotechs, Vignette Bio and TRC 2004. • The company's pipeline includes two T-cell engagers, targeting BCMA and CD20, which have completed Phase 1 testing in cancer and are slated for autoimmune clinical trials next year. • Candid aims to offer a more commercially viable and convenient alternative to cell therapies for autoimmune diseases, leveraging the potential of bispecific antibodies. • CEO Ken Song believes T-cell engagers represent a transformative approach, citing encouraging case reports and growing industry interest in the field.